CONTRACT NUMBER HP06-2012SVP THE DEPARTMENT OF … · Novartis South Africa (Pty) Ltd P O Box 92...

2

CONTRACT NUMBER HP06-2012SVP PROVISION OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH PERIOD 1 JUNE 2012 TO 31 MAY 2014 1. IMPORTANT GENERAL INFORMATION: 1.1 Please note that the delivered price is for the unit of measure (UOM) offered. 1.2 All prices are inclusive of 14 % VAT. 1.3 All prices are on a delivered basis. 1.4 Should an order be placed by any institution other than the provincial medical

depots, the validity of the order must first be confirmed with the relevant depot manager.

1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name POSTAL ADDRESS Contact person Name & e‐mail Telephone Number Fax Number

Supplier Code

Abbott Laboratories SA (Pty) Ltd P O Box 7208 WELTEVREDEN PARK 1715

Stephanie Takacs [email protected]

Tel: (011) 858‐2000/ (011) 858‐2122 Fax: (011) 858‐2048

V2150

Adcock Ingram Critical Care (Pty) Ltd

P O Box 6888, JOHANNESBURG 2000

Tahera Munshi [email protected]

Tel: (011) 494‐8000/ (011) 635‐0000 Fax: 086‐553‐0640

V4222

Adcock Ingram Healthcare (Pty) Ltd

Private Bag X69 BRYANSTON 2021

Louis [email protected]

Tel: (011) 635‐0671 Fax: 086‐553‐06711

V2272

Alcon Laboratories (SA) (Pty) Ltd P O: Box 3198 RANDBURG 2125

Tim Borland [email protected]

Tel: (011) 840‐2300 Fax: (011) 840‐2301

V6308

B Braun Medical (Pty) Ltd P O Box 1787 RANDBURG 2125

Walda van Zyl [email protected]

Tel: (011) 222‐3000 Fax: (011) 222‐3048

VYL89

Bayer (Pty) Ltd P O Box 143 ISANDO 1600

Charl Botes [email protected]

Tel: (011) 921‐5279/ (011) 921‐5842 Fax: (011) 921‐5272/ 086‐639‐6960

V6390

Biotech Laboratories (Pty) Ltd Suite 15D Private Bag X65 HALFWAY HOUSE 1685

S K Mapetla [email protected] [email protected]

Tel: (011) 848‐3050 Fax: (011) 848‐3065

VUV35

Eli Lilly South Africa (Pty) Ltd Private Bag X119 BRYANSTON 2021

Luis M G Freitas [email protected]

Tel: (011) 510‐9320/ (011) 510‐9300 Fax: (011) 510‐9301

V2181

3

Supplier Name POSTAL ADDRESS Contact person Name & e‐mail Telephone Number Fax Number

Supplier Code

Fresenius Kabi South Africa (Pty) Ltd

P O Box 4156 HALFWAY HOUSE 1685

Albertha Nel albertha.nel@fresenius‐kabi.com

Tel: (011) 545‐0000 Fax: (011) 545‐0060

VAJL3

Ingelheim Pharmaceuticals (Pty) Ltd

Private Bag X3032 RANDBURG

Phillipus Jacobus Brits jo.warden@boehringer‐ingelheim.com

Tel: (011) 348‐2480 Fax: 086‐528‐9171

VH649

Janssen Pharmaceutica (Pty) Ltd P O Box 785939 SANDTON 2146

Jakobus D Venter [email protected]

Tel: (011) 518‐7000 Fax: 086‐673‐9513

VBKY6

Litha Pharma (Pty) Ltd P O Box 8356 MIDRAND 1685

Martin Michael Kahanovitz [email protected]

Tel: (011) 516‐1700 Fax: 087‐642‐1660

To Follow

Lundbeck South Africa (Pty) Ltd P O Box 2171NORTH RIDING2162

Sue Bester [email protected]

Tel: (011) 699‐1600 Fax: (011) 699‐1657

VVS90

MSD (Pty) Ltd Private Bag 3 HALFWAY HOUSE 2185

Mmathuto Malape [email protected]

Tel: (011) 655‐3357/ (011) 655‐3037 Fax: (011) 655‐3429/ (011) 655‐3187

V2185

Novartis South Africa (Pty) Ltd P O Box 92 ISANDO 1600

Nkosinathi Mthethwa [email protected]

Tel: (011) 929‐9111 Fax: (011) 929‐2264

VBVW2

Novo Nordisk P O Box 783115 SANDTON 2146

Moloele Timothy Kedijang [email protected]

Tel: (011) 202‐50500 Fax: (011) 807‐4252

V2743

Nycomed (Pty) Ltd P O Box 70086 BRYANSTON 2021

Debro Ransby [email protected] [email protected]

Tel: (011) 514‐3000/ Fax: (011) 514‐3111 086‐558‐9408

V6300

Pfizer Laboratories (Pty) Ltd P O Box 783720 SANDTON 2146

Themba [email protected]

Tel: (011) 320‐6000 Fax: (011) 895‐1491

V2189

Pharmacare Limited P O Box 4002 KORSTEN 6014

Alan Gordon Beattie [email protected]

Tel: (041) 407‐2260 Fax: (041) 409‐3223

V2205

Pharmachem Pharmaceuticals Private Bag X12 PRETORIA WEST 0117

Omar Matthews [email protected]

Tel: (012) 327‐7754 Fax: 086‐674‐7333

V18V6

Pharma‐Q (Pty) Ltd Private Bag X09 FLORIDA 1710

Anand Mehta [email protected]

Tel: (011) 247‐1600 Fax: 086‐652‐8211

V1NK1

Roche Products (Pty) Ltd P O Box 55922 NORTHLANDS 2196

Theo Thiart [email protected]

Tel: (011) 502‐5000 Fax: (011) 268‐5768

V2177

Sanofi‐Aventis South Africa (Pty) Ltd

Private Bag X207 MIDRAND 1683

Mary [email protected] [email protected]

Tel: (011) 2563809 Fax: (011) 2563917

V2160

Specpharm (Pty) Ltd P O Box 651 HALFWAY HOUSE MIDRAND 1685

Jaidev Maharaj [email protected]

Tel: (011) 652‐0428 Fax: 086‐211‐3266

VCEH8

HP06‐2012SVP CONTRACT CIRCULAR 10092012‐ Including Add 2

HP06‐2012SVP: Supply and Delivery of Small Volume Parenterals and Insulin Devices to the Department of Health for the period 1 June 2012 to 31 May 2014

Item No.

Description Quantity Awarded

Supplier Name Code Split Deliverd Price Brand name Unit Pack Lead Time (Days)

Minimum Order

Total Points

NSN

1 ADENOSINE 3mg/ml injection, 2ml ampoule/vial

25,390 Sanofi‐Aventis South Africa

V2160 R 71.3100 Adenocor Vial 6mg / 2ml 1 42 6 93.00 18‐037‐3081 (VI)

2 ADRENALINE 1mg/ml (1:1000) injec on, 1ml ampoule

3,200,800 Fresenius Kabi SA (Pty) Ltd

VAJL3 R 1.4600 Adrenaline ‐ Fresenius 1mg/ml (1:1000) Amp

10 30 10 93.00 18‐007‐5485(AM)

3 ALFENTANIL 0,5mg/ml injection, 2ml ampoule [S6]

96,270 Janssen Pharmaceutica VBKY6 R 36.1100 Rapifen 2ml 1 amp 42 5 90.00 18‐007‐5489(AM)

4 ALPROSTADIL 0,5mg injection, 1ml ampoule

2,440 Pfizer Laboratories (Pty) Ltd

V2189 R 1,790.1140 Prostin VR 0.5mg inj 5 42 5 90.00 18‐007‐5498(AM)

5 ALPROSTADIL 20mcg injection, 1ml ampoule

70 Pfizer Laboratories (Pty) Ltd

V2189 R 131.2610 Caverject 20mcg inj 1 42 1 90.00 18‐020‐8246(VI)

6 AMINOPHYLLINE 25mg/ml injection, 10ml ampoule For IV use

343,010 Fresenius Kabi SA (Pty) Ltd

VAJL3 R 4.3400 Aminophyllin IV ‐ Fresenius 250mg Amp

10 30 10 93.00 18‐970‐0102(AM)

7 AMIODARONE HCI 50mg/ml injec on, 3ml ampouleTo be labeled 'Dilute with 5% dextrose only'

92,150 Pharmacare Limited V2205 R 33.4932 Amiotach Inj 150mg/3ml 150mg/3ml Amp

42 1 x 5 98.00 18‐007‐5509(AM)

9 ATRACURIUM BESYLATE 10mg/ml injec on, 2,5ml ampoule

134,700 Pharmacare Limited V2205 R 44.0724 Tracrium Inj 2,5ml 2,5ml Amp 42 3 x 5 98.00 18‐007‐5518(AM)

10 ATRACURIUM BESYLATE 10mg/ml, 5ml ampoule

31,540 Pharmacare Limited V2205 R 57.9576 Tracrium Inj 5ml 5ml Amp 42 3 x 5 98.00 18‐007‐5520(AM)

450,506 Pharma‐Q (Pty) Ltd V1NK1 70% R 1.5800 Pharma‐Q Atropine 0.5mg 10 42 650 98.00 18‐970‐7023(AM)

193,074 Adcock Ingram Critical Care (Pty) Ltd

V4222 30% R 1.6300 Sabax Atropine 0,5 mg/ml 1 ml 10 amps 1‐6 weeks ex stock

1 Box 92.15 18‐970‐7023(AM)

12 ATROPINE SULPHATE 1mg injection, 1ml ampoule

377,640 Pharma‐Q (Pty) Ltd V1NK1 R 1.6800 Pharma‐Q Atropine 1mg 10 42 600 98.00 18‐970‐7024(AM)

13 BETAMETHASONE 4mg injection, 1ml ampoule

337,210 Pharma‐Q (Pty) Ltd V1NK1 R 2.3300 Pharma‐Q Betamethasone 10 42 450 98.00 18‐007‐5545(AM)

14 BETAMETHASONE DISODIUM PHOSPHATE 3mgBETAMETHASONE ACETATE 3mg injec on, 1ml ampoule

354,150 MSD (Pty) Ltd V2185 R 21.0000 Celestone Soluspan 1ml 28 10 x 1ml 90.00 18‐007‐5543(AM)

15 BETAMETHASONE DISODIUM PHOSPHATE 3mgBETAMETHASONE ACETATE 3mg/ml injec on, 5ml vial

4,090 MSD (Pty) Ltd V2185 R 105.0000 Celestone Soluspan 5ml 28 10 x 5 ml 90.00 18‐971‐0894(VI)

11

ATROPINE SULPHATE 0.5mg injec on, 1ml ampoule

Add 1 2 Corrections included Page 1 of 15 Period: 1 June 2012 ‐ 31 May 2014


Item No.



Minimum Order

Total Points

NSN

17 BUPIVACAINE HCI 5mg/ml injection, 4ml ampoule For Spinal Anaesthesia

76,310 Adcock Ingram Healthcare

V2272 R 10.7620 Macaine Spinal 10 x 4 ml 42 1 x 10 x 4ml 95.00 18‐007‐5553(AM)

18 BUPIVACAINE HCI 5mg/ml injection, 10ml ampoule

492,720 Pharma‐Q (Pty) Ltd V1NK1 R 3.2000 Pharma‐Q Bupivacaine 10 42 300 98.00 18‐007‐5551(AM)

19 BUPIVACAINE HCI 5mgADRENALINE 5mcg/ml injection, 20ml ampoule


V2272 R 16.6420 Macaine w/adrenaline 10 x 20ml 42 1 x 10 x 20ml 95.00 18‐007‐5555(AM)

20 BUPIVACAINE HCI 5mgDEXTROSE ANHYDROUS 72,7mg/ml injec on, 4ml ampoule

518,190 Pharma‐Q (Pty) Ltd V1NK1 R 3.4400 Pharma‐Q Bupivacaine spinal with Dextrose

10 42 300 98.00 18‐007‐5556(AM)

21 CALCIUM CHLORIDE 10% m/v injec on, 10ml ampoule


V4222 R 2.2700 Sabax Calcium Chlor 10% 10 ml 10 amps 1‐6 weeks ex stock

1 Box 95.00 18‐007‐5562(AM)

22 CALCIUM GLUCONATE 10% m/v injec on, 10ml ampouleFor IM and IV use


VAJL3 R 4.3300 Calcium Gluconate ‐ Fresenius Amp 10 30 10 93.00 18‐007‐5565(AM)

23 CHLORPROMAZINE HCI 25mg injec on, 1ml ampoule


VAJL3 R 3.0200 Chlorpromazine HCI ‐ Fresenius 25mg Amp

10 30 10 93.00 18‐007‐5625(AM)

24 CHLORPROMAZINE HCI 25mg/ml injec on, 2ml ampoule


VAJL3 R 2.3900 Chlorpromazine HCI ‐ Fresenius 50mg Amp

10 30 10 93.00 18‐007‐5629(AM)

563,526 Pharma‐Q (Pty) Ltd V1NK1 60% R 1.5400 Pharma‐Q Cimetidine 10 42 650 98.00 18‐007‐5649(AM)


V4222 40% R 1.5420 Sabax Cimetidine 200 mg/2 ml 10 amps 1‐6 weeks ex stock

1 box 95.00 18‐007‐5649(AM)

27 CISATRACURIUM BESYLATE 2mg/ml injec on, 2,5ml ampoule

53,370 Pharmacare Limited V2205 R 36.8220 Nimbex 2mg/ml Inj 2.5ml 2,5ml Amp 42 2 x 5 98.00 18‐176‐7288(AM)

28 CISATRACURIUM BESYLATE 2mg/ml injection, 5ml ampoule

26,580 Pharmacare Limited V2205 R 51.4710 Nimbex 2mg/ml Inj 5ml 5ml Amp 42 2 x 5 98.00 18‐030‐8024(AM)

29 CLONAZEPAM 1mg/ml injection, 1ml ampoule + 1ml diluent

262,340 Roche Products (Pty) Ltd V2177 R 21.3400 Rivotril 1mg/ml ampoules 5 28 5 91.00 18‐007‐5726(AM)

30 CLOTHIAPINE 10mg/ml injection, 4ml ampoule

93,660 Novartis S A (Pty) Ltd VBVW2 R 10.9900 Etomine 10mg/ml injection amp 10 42 10 91.00 18‐007‐5729(AM)

31 CYPROTERONE ACETATE 100mg/ml injec on, 3ml ampoule

28,360 Bayer (Pty) Ltd V6390 R 123.2800 Androcur Depot 3 x 3ml 14 3 x 3ml 90.00 18‐009‐0442(AM)

32 DALTEPARIN SODIUM 2 500 iu/0,2ml injec on, prefilled syringe


V2189 R 14.7000 Fragmin 2500IU /0.2ml PFS 0.5ml 10 42 10 90.00 18‐024‐7839(SG)

26CIMETIDINE 100mg/ml injection, 2ml ampoule



Item No.



Minimum Order

Total Points

NSN

33 DALTEPARIN SODIUM 5 000 iu/0,2ml injec on, prefilled syringe


V2189 R 28.1600 Fragmin 5000IU /0.2ml PFS 0.5ml 10 42 10 90.00 18‐024‐7844(SG)

35 DESFERRIOXAMINE MESYLATE 500mg powder for injec on, vial

72,400 Novartis S A (Pty) Ltd VBVW2 R 67.8100 Desferal 500mg injection powder 10 42 10 91.00 18‐007‐5755(VI)

1,729,200 PHARMA‐Q (PTY) LTD V1NK1 80% R 3.0300 Pharma‐Q Dexamethasone Phosphate 10 42 300 98.00 18‐007‐5759(AM)

432,300 Biotech Laboratories (Pty) Ltd

VUV35 20% R 3.3800 Dexona 4mg/ml Injection 1ml ampoule 21 300 79.60 18‐007‐5759(AM)

38 DEXTROSE 50% m/v injection, 20ml ampouleAs anhydrous Dextrose or Dextrose Monohydrate in Water for Injec ons.For IV Infusion. Clear glass ampoule or suitable clear plas c container


VAJL3 R 12.3900 Dextrose ‐ Fresenius 50% 20ml Amp 10 30 10 93.00 18‐007‐5794(AM)

39 DEXTROSE 50% m/v injection, 50ml ampouleAs Anhydrous Dextrose or Dextrose Monohydrate in Water for Injec ons.For IV Infusion. Clear glass ampoule or suitable clear plas c container


VAJL3 R 22.9000 Dextrose ‐ Fresenius 50% 50ml Bag 1 30 50 93.00 18‐035‐2804(BG)

40 DIAZEPAM 5mg/ml injection, 2ml ampoule

665,580 PHARMA‐Q (PTY) LTD V1NK1 R 1.5600 Pharma‐Q Diazepam 10 42 650 98.00 18‐007‐5798(AM)

41 DICLOPHENAC SODIUM 25mg/ml injec on, 3ml ampoule

5,075,050 Pharmachem Pharmaceuticals (Pty) Ltd

V18V6 R 0.7700 Difenject VIAL 42 500 90.00 18‐007‐5799(AM)

42 DIGOXIN 0,25mg/ml injection, 2ml ampoule

48,710 Pharmacare Limited V2205 R 14.4780 Lanoxin Inj 0.25mg/ml 2ml Amp 42 2 x 5 98.00 18‐007‐5803(AM)

43 DIHYDROCODEINE TARTRATE 50mg injec on, 1ml ampoule [S6]

16,330 Pharmacare Limited V2205 R 44.0724 DF 118 Inj 50mg 1ml Amp 42 1 x 5 98.00 18‐971‐0756(AM)

44 DINOPROST 5mg injection, 1ml ampoule


V2189 R 98.1200 Prostin F2 Alpha 5mg/ml INJ 1ml 1 42 1 90.00 18‐971‐0758(AM)

45 DOBUTAMINE HCl 12,5mg/ml injec on, 20ml vial


VAJL3 R 19.4900 Dobutamine ‐ Fresenius 250mg/20ml Amp

5 42 5 93.00 18‐971‐5235(VI)

37DEXAMETHASONE 4mg injection, 1ml ampoule



Item No.



Minimum Order

Total Points

NSN

46 DOPAMINE HCI 40mg/ml injection, 5ml ampouleMust have a strip label printed RED ON WHITE or BLACK ON RED, over the neck of the ampoule stating: 'MUST BE DILUTED/MOET VERDUN WORD'

89,090 PHARMA‐Q (PTY) LTD V1NK1 R 2.9800 Pharma‐Q Dopamine 10 42 350 92.98 18‐007‐5879(AM)

47 DROPERIDOL 2.5mg/ml, 2 ml ampoule

15,820 Janssen Pharmaceutica V6205 R 43.1700 Inapsin 1 amp 42 5 90.00 18‐970‐5126(AM)

48 ENOXAPARIN 40mg injection, 0,4ml prefilled syringe

2,097,910 Sanofi‐Aventis South Africa

V2160 R 19.3800 Clexane PFS 40mg 1 42 10 93.00 18‐007‐7964(SG)

49 ENOXAPARIN 60mg injection, 1ml prefilled syringe



50 ENOXAPARIN 80mg injection, 1ml prefilled syringe



51 ENOXAPARIN 300mg injection, mul dose vial

910 Sanofi‐Aventis South Africa

V2160 R 118.5600 Clexane Mulitdose 300mg 1 42 1 93.00 18‐179‐9369(SG)

52 EPHEDRINE SULPHATE 50mg injection, 1ml ampoule [S6]

249,220 Abbott Laboratories SA (Pty) (Ltd)

V2150 R 29.9500 Ephedrine Sulphate 10 42 10 92.00 18‐971‐3748(AM)

53 EPTIFIBATIDE 0,75mg/ml injection, 100ml vial

150 MSD (PTY) LTD V2185 R 1,463.5700 Integrillin 0.75 mg/ml 1 x 100ml vial 28 1 90.00 18‐032‐7849(VI)

54 EPTIFIBATIDE 2mg/ml injection, 10 ml vial

270 MSD (PTY) LTD V2185 R 487.9700 Integrillin 2mg/ml 1 x 10ml vial 28 1 90.00 18‐032‐7848(VI)

55 ERGOMETRINE MALEATE 0,5mg injec on, 1ml ampoule


VAJL3 R 4.4100 Ergometrine Maleate ‐ Fresenius 0.5mg/ml Amp

10 30 10 93.00 18‐007‐5885(AM)

57 ERYTHROPOIETIN, RECOMBINANT HUMAN 2 000 iu injection, 0,5ml prefilled syringeFor IV/Subcutaneous use

135,790 ROCHE PRODUCTS (PTY) LTD

V2177 R 49.7500 Recormon 2000 IU/0,3 ml 6 28 6 91.00 18‐025‐0265(SG)

58 ERYTHROPOIETIN, RECOMBINANT HUMAN 30 000 iu injection, 0.6ml. Prefilled syringe For IV/Subcutaneous use

370 ROCHE PRODUCTS (PTY) LTD


59 ERYTHROPOIETIN, RECOMBINANT HUMAN 4 000 iu injection, 0,4ml prefilled syringeFor IV/Subcutaneous use



60 ERYTHROPOIETIN, RECOMBINANT HUMAN 10 000 iu injection, 1ml prefilled syringeFor IV/Subcutaneous use





Item No.



Minimum Order

Total Points

NSN

61 ETILEFRINE HCI 10mg injection, 1ml ampoule

83,010 Ingelheim Pharmaceuticals (Pty) Ltd

VH649 R 68.0100 Effortil 10 mg/1 ml Ampoule 1 14 1 90.00 18‐007‐5955(AM)

62 ETOMIDATE 2mg/ml injection, 10ml ampoule

82,540 B Braun Medical (Pty) Ltd

VYL89 R 33.6300 Etomidate 2mg/ml injection, 10ml 10 per box 42 To be advised

91.00 18‐007‐5956(AM)

63 FENTANYL 0,05mg/ml injection, 2ml ampoule[S6]


VAJL3 R 1.3300 Fentanyl ‐ Fresenius 100mcg/2ml Amp 10 30 10 93.00 18‐007‐5959(AM)

64 FENTANYL 0,05mg/ml injection, 10ml ampoule[S6]

50,120 PHARMA‐Q (PTY) LTD V1NK1 R 3.7800 Pharma‐Q Fentanyl 10 42 260 98.00 18‐007‐5960(AM)

65 FLUMAZENIL 0,1mg/ml injection, 5ml ampoule


V2177 R 211.8300 Anexate 0.5 mg 1 28 1 91.00 18‐971‐2783(AM)

66 FLUMAZENIL 0,1mg/ml injection, 10ml ampoule


V2177 R 347.5100 Anexate 1.0 mg 1 28 1 90.00 18‐971‐1614(AM)

68 FLUORESCEIN 100 mg/ml injection, 5ml ampoule For IV Infusion

3,020 Alcon Laboratories (SA) (Pty) Ltd

V6308 R 125.8400 Fluorescite 10% 12 5 12 x 5 ml 94.00 18‐183‐7484(VI)

69 FLUPENTHIXOL DECANOATE 20mg injec on, 1ml ampoule

870,310 Lundbeck SA Pty Ltd VVS90 R 26.4200 Fluanxol Depot 20mg 1 x 5 10 5 x 5 90.00 18‐001‐7761(AM)

72 FUROSEMIDE 10mg/ml injection, 2ml ampoule

3,938,500 Adcock Ingram Critical Care (Pty) Ltd

V4222 R 1.0830 Sabax Furosemide 20 mg/2 ml Each ,10 amps

1 ‐ 6 weeks ex stock

1 box of 10 ampoules

95.00 18‐007‐5982(AM)Add 1 & 2


239,780 PHARMA‐Q (PTY) LTD V1NK1 R 2.3900 Pharma‐Q Furosemide 10 42 420 98.00 18‐007‐5985(AM)



VAJL3 R 12.1800 Furosemide ‐ Fresenius 250mg/25ml Amp

10 30 10 93.00 18‐007‐5988(AM)

75 GLUCAGON 1mg vial including diluent and syringe

10,270 Novo Nordisk (Pty) Ltd V2743 R 216.6000 Glucagon Hypokit 1 10 1 92.00 18‐030‐9135(VI)

82 HEPARIN SODIUM 1 000 iu/ml injec on, 5ml vialStrength to be clearly stated on label


VAJL3 R 10.7700 Heparin ‐ Fresenius 1000 iu/ml 5ml Vial

10 30 10 93.00 18‐971‐5772(VI)



VAJL3 R 20.0000 Heparin ‐ Fresenius 5000 iu/ml 5ml vial

10 30 10 93.00 18‐971‐0951(VI)



VAJL3 R 119.7000 Heparin ‐ Fresenius 25000 iu/ml 5ml Vial

10 30 10 93.00 18‐007‐6016(VI)

85 HYDROCORTISONE 100mg injection, vial(as Sodium succinate)

2,112,050 Pfizer Laboratories (Pty) Ltd

V2189 R 10.8700 Solu‐Cortef 100mg/2ml PDR for INJ 5 42 5 90.00 18‐001‐8040(VI)



Item No.



Minimum Order

Total Points

NSN

86 HYDROXYZINE HYDROCHLORIDE 50mg/ml injec on, 2ml ampoule

198,390 PHARMA‐Q (PTY) LTD V1NK1 R 2.9900 Pharma‐Q Hydroxyzine HCL 10 42 350 98.00 18‐008‐9469(AM)

87 HYOSCINE‐N‐BUTYLBROMIDE 20mg injec on, 1ml ampoule

1,489,490 PHARMA‐Q (PTY) LTD V1NK1 R 1.9100 Pharma‐Q Hyoscine‐n‐Butylbromide 10 42 520 98.00 18‐007‐6081(AM)

90 INSULIN, HUMAN Ultrafast acting insulin analogue 100 units/ml, 3ml prefilled syringe

79,770 Eli Lilly SA (Pty) Ltd V2181 R 50.2100 Humalog 3ml Kwikpen 1 30 1 93.00 18‐175‐1347(SG)

91 INSULIN, HUMAN, ultra‐fast acting insulin analogue 100units/mL 10ml

1,490 Eli Lilly SA (Pty) Ltd V2181 R 85.3900 Humalog 10ml Kwikpen 1 30 1 93.00 18‐018‐8076(VI)

92 INSULIN, ISOPHANE, HUMAN 100 units/ml injection, 3ml prefilled syringe BIOSYNTHETIC

1,510,300 Novo Nordisk (Pty) Ltd V2743 R 25.1630 Protaphane (HM) GE Flexpen 5 10 5 92.00 18‐030‐9126(SG)


V2160 60% R 22.8000 Insuman Basal 10ml 1 42 1 93.00 18‐971‐0587(VI)

181,028 Novo Nordisk (Pty) Ltd V2743 40% R 22.8850 Protaphane (HM) GE Vial 1 10 1 91.66

94 INSULIN, SOLUBLE, HUMAN 100 units/ml injection, 3ml prefilled syringe BIOSYNTHETIC

632,460 Novo Nordisk (Pty) Ltd V2743 R 25.1630 Actrapid (HM) GE Flexpen 5 10 5 92.00 18‐030‐9128(SG)


V2160 60% R 22.8000 Insuman Rapid 10ml 1 42 1 93.00 18‐971‐0585(VI)

99,292 Novo Nordisk (Pty) Ltd V2743 40% R 22.8850 Actrapid (HM) GE Vial 1 10 1 91.66

96 INSULIN, SOLUBLE, HUMAN 30%INSULIN, ISOPHANE, HUMAN 70% in 100 units/ml, 3ml prefilled syringe BIOSYNTHETIC

4,341,870 Novo Nordisk (Pty) Ltd V2743 R 25.1630 Actraphane (HM) GE Flexpen 5 10 5 92.00 18‐030‐9129(SG)

1,885,818 Sanofi‐Aventis South Africa

V2160 60% R 22.8000 Insuman Comb 30/70 1 42 1 93.00 18‐971‐1634(VI)

1,257,212 Novo Nordisk (Pty) Ltd V2743 40% R 22.8850 Actraphane (HM) GE Vial 1 10 1 91.66

95

93

INSULIN, SOLUBLE, HUMAN 30%INSULIN, ISOPHANE, HUMAN 70% in 100 units/ml, 10ml vialBIOSYNTHETIC

INSULIN, SOLUBLE, HUMAN 100 units/ml injec on, 10ml vialBIOSYNTHETIC

INSULIN, ISOPHANE, HUMAN 100 units/ml injec on, 10ml vialBIOSYNTHETIC

97



Item No.



Minimum Order

Total Points

NSN

98 IRON (III) HYDROXIDE DEXTRAN COMPLEX AMPOULES equivalent to ELEMENTAL IRON 500mg, 10ml glass ampouleFor IV use only

1,520 Litha Pharma (Pty) Ltd VGS73 R 285.0000 Cosmofer 1 x 5ml ampoules

42 1 x 5 95.00 18‐187‐1852(AM)

Add 199 IRON (III) HYDROXIDE DEXTRAN

COMPLEX AMPOULES equivalent to ELEMENTAL IRON 50mg/2ml glass ampouleFor IV use only

1,520 Litha Pharma (Pty) Ltd VGS73 R 57.0000 Cosmofer 1 x 5ml ampoules

42 2 x 5 95.00 18‐189‐1028(AM)

Add 1100 IRON (III) HYDROXIDE SUCROSE

COMPLEX injection equivalent to ELEMENTAL IRON 100mg, 5ml glass ampouleFor IV use only

93,490 Nycomed (Pty) Ltd V6300 R 68.4000 Venofer 5 7 10 90.00 18‐018‐5678(AM)

Add 2101 IRON POLYMALTOSE equivalent to

ELEMENTAL IRON 100mg injection, 2ml ampoule For IM use only

56,230 Nycomed (Pty) Ltd V6300 R 68.4000 Ferrimed 5 7 10 90.00 18‐007‐0808(AM)

Add 2102 KETAMINE HCI 10mg/ml injection,

20ml vial 19,400 Fresenius Kabi SA (Pty)

LtdVAJL3 R 26.0500 Ketamine ‐ Fresenius 10mg/ml Vial 10 30 10 93.00 18‐971‐0933(VI)

103 KETAMINE HCI 50mg/ml injection, 10ml vial


VAJL3 R 34.2000 Ketamine ‐ Fresenius 50mg/ml Vial 10 30 10 93.00 18‐971‐0574(VI)

104 KETAMINE HCI 100mg/ml injection, 10ml vial


VAJL3 R 68.4000 Ketamine ‐ Fresenius 100mg/ml Vial 10 30 10 93.00 18‐970‐6747(VI)

105 LABETALOL HCI 5mg/ml injection, 20ml ampouleFor IV use

62,160 Pharmacare Limited V2205 R 193.0020 Trandate Inj 20ml 20ml Amp 42 1 x 5 98.00 18‐007‐6305(AM)

106 LIGNOCAINE HCI 1% m/v injection, 20ml mul dose vialVials to be distinctly labelled 'not for intravenous use'


VAJL3 R 4.8800 Lignocaine HCI ‐ Fresenius 1% Vial 10 30 10 86.47 18‐007‐6306(VI)

107 LIGNOCAINE HCI 2% m/v injection, 20ml mul dose vialVials to be distinctly labelled 'not for intravenous use'


VAJL3 R 4.9800 Lignocaine HCI ‐ Fresenius 2% Vial 10 30 10 89.43 18‐970‐3157(VI)

108 LIGNOCAINE HCI 2% m/v injection, 5ml ampoule (Without preserva ve) For IV use

724,760 B Braun Medical (Pty) Ltd

VYL89 R 2.0500 Lignocaine 2% 5ml 20 per box 42 5 boxes 91.00 18‐007‐6308(AM)



Item No.



Minimum Order

Total Points

NSN

109 LIGNOCAINE HCI 10% m/v injection, 5ml ampoule.Ampoule must be labelled: For addition to infusion solution only. Suitable for intravenous use. Each immediate container must have a strip label over the neck of the ampoule, printed RED ON WHITE, stating 'MUST BE DILUTED/MOET VERDUN WORD'. WITHOUT PRESERVATIVE.

21,740 Fresenius Kabi South Africa (Pty) Ltd

VAJL3 R 5.70 Lignocaine HCI ‐ Fresenius 10%Amp 10 30 10 93.00 18‐007‐6360(AM)

110 LIGNOCAINE HCI 2% m/v injection, 1,8ml dental cartridge(Without ADRENALINE)For use in den stry and other indications

2,168,750 Adcock Ingram Healthcare

V2272 R 2.4596 Xylolox 2% SE 100 x 1.8ml 42 1 x 100ml x 1.8ml

95.00 18‐007‐6343(CA)

111 LIGNOCAINE HCI 2% m/vADRENALINE 12.5mcg (1:80 000) Dental Cartridge 1.8ml

7,924,650 Adcock Ingram Healthcare

V2272 R 2.4596 Xylolox E80A 100 x 1.8ml 42 1 x 100ml x 1.8ml

95.00 18‐007‐6312 (CA)

Add 1114 MAGNESIUM SULPHATE 50% m/v

injec on, 2ml ampoule 2,757,440 Adcock Ingram Critical

Care (Pty) LtdV4222 R 1.6400 Sabax Mag Sulph 50% 2 ml 10 amps 1‐6 weeks ex

stock1 Box 95.00 18‐971‐0942(AM)

115 MANNITOL 25% m/v injection, 50ml ampoule clear glass ampoule or suitable clear plas c container


VAJL3 R 32.2400 Mannitol 25% 50ml 1 30 50 93.00 18‐020‐8630(BG)

116 MEPIVACAINE HCI 54mg injection, 1,8ml dental cartridge


V2272 R 3.0346 Carbocaine 3% 100 x 1.8ml 42 1 x 100ml x 1.8ml

95.00 18‐970‐5645(CA)

117 METHYLPREDNISOLONE 40mg powder for injec on, 1ml vial(as Sodium succinate)


V2189 R 22.6900 Solu‐Medrol AOV 40mg 1ml inj 1 42 1 90.00 18‐975‐9248(VI)

118 METHYLPREDNISOLONE 125mg powder for injec on, 2ml vial(as Sodium succinate)



119 METHYLPREDNISOLONE 500mg powder for injection, 8ml vial + diluent(as Sodium succinate)



120 METHYLPREDNISOLONE 1 000mg powder for injection, 16ml vial + diluent(as Sodium succinate)



121 METHYLPREDNISOLONE ACETATE 40mg/ml injec on, 1ml vial


V2189 R 14.3800 Depo‐Medrol 40mg/ml 1ml inj 1 42 1 90.00 18‐971‐5290(VI)



Item No.



Minimum Order

Total Points

NSN








V4222 80% R 1.1910 Sabax Metoclopramide 10 mg/2 ml ampoule

10 amps 1‐6 weeks ex stock

1 Box 95.00 18‐007‐6396 (AM)

Add 2 645,106 PHARMA‐Q (PTY) LTD V1NK1 20% R 1.4500 Pharma‐Q Metoclopramide 10 42 650 77.67 18‐007‐6396 (AM)

125 MIDAZOLAM 1mg/ml, 5ml ampoule 410,200 PHARMA‐Q (PTY) LTD V1NK1 R 4.0000 Pharma‐Q Midazolam 10 42 250 98.00 18‐007‐6401(AM)

126 MIDAZOLAM 5mg/ml injection, 3ml ampoule

555,810 PHARMA‐Q (PTY) LTD V1NK1 R 4.1000 Pharma‐Q Midazolam 5 42 250 98.00 18‐007‐6404(AM)

127 MIDAZOLAM 5mg/ml injection, 10ml vial

51,700 PHARMA‐Q (PTY) LTD V1NK1 R 33.3300 Pharma‐Q Midazolam 10 42 250 98.00 18‐001‐8352(AM)

128 MIVACURIUM 2mg/ml injection, 5ml ampoule

1,590 Pharmacare Limited V2205 R 74.1000 Mivacron 2mg/ml Inj 5ml 5ml Amp 42 1 x 5 98.00 18‐018‐7133(AM)

129 MORPHINE SULPHATE 10mg injec on, 1ml ampoule[S6]


VAJL3 R 1.1900 Morphine Sulphate ‐ Fresenius 10mg/ml Amp

10 30 10 93.00 18‐970‐3413(AM0

130 MORPHINE SULPHATE 15mg injec on, 1ml ampoule[S6]


VAJL3 R 1.2000 Morphine Sulphate ‐ Fresenius 15mg/ml Amp

10 30 10 93.00 18‐970‐0425(AM)

131 MORPHINE HYDROCHLORIDE 13,44mg, PAPAVERINE HYDROCHLORIDE 1,20mg, CODEINE HYDROCHLORIDE 1,04mg injection, 1ml ampoule [S6]


VAJL3 R 11.0400 Omnopon ‐ Fresenius 20mg/ml Amp 10 30 10 93.00 18‐007‐9726(AM)

132 NALOXONE HCI 0,02mg/ml injection, 2ml ampoule


VAJL3 R 3.9900 Naloxone HCI ‐ Fresenius 0.02mg/ml Amp

10 30 10 93.00 18‐970‐8068(AM)

133 NALOXONE HCI 0,4mg injection, 1ml ampoule


VAJL3 R 2.2800 Naloxone HCI ‐ Fresenius 0.4mg/ml Amp

10 30 10 93.00 18‐970‐5061(AM)

134 NEOSTIGMINE METHYLSULPHATE 0,5mg injec on, 1ml ampoule


VAJL3 R 3.8200 Neostigmine ‐ Methylsulphate ‐ Fresenius 0.5mg/ml Amp

10 30 10 93.00 18‐007‐6423(AM)

135 NEOSTIGMINE METHYLSULPHATE 2,5mg injec on, 1ml ampoule


VAJL3 R 1.7100 Neostigmine ‐ Methylsulphate ‐ Fresenius 2.5mg/ml Amp

10 30 10 93.00 18‐008‐9506(AM)

124

METOCLOPRAMIDE MONOHYDROCHLORIDE 5mg/ml injec on, 2ml ampoule



Item No.



Minimum Order

Total Points

NSN

136 NIMODIPINE 10mg injection, 50ml vialFor IV Infusion

1,810 Bayer (Pty) Ltd V6390 R 233.8600 Nimotop IV 1 x 50ml 14 1 x 50ml 90.00 18‐976‐3129(VI)

137 OCTREOTIDE 0,05mg injection, 1ml ampoule

1,130 Novartis S A (Pty) Ltd VBVW2 R 76.4600 Sandostatin 0.05mg injection, amp 5 42 5 91.00 18‐007‐6442(AM)

138 OCTREOTIDE 0,1mg injection, 1ml ampoule

21,060 Novartis S A (Pty) Ltd VBVW2 R 145.8700 Sandostatin 0.1mg injection, amp 5 42 5 91.00 18‐007‐6445(AM)

139 OCTREOTIDE 0,2mg/ml injection, 5ml mul dose vial

4,450 Novartis S A (Pty) Ltd VBVW2 R 1,252.9100 Sandostatin 0.2mg injection, amp 1 42 1 91.00 18‐971‐4924(VI)

140 OESTROGENS, CONJUGATED 25mg injection, vial


V2189 R 217.2940 Premarin 25mg PDR for INJ 1 42 1 90.00 18‐971‐0759(VI)

963,312 Specpharm (Pty) Ltd VCEH8 80% R 3.7848 Spec‐Oxytocin 5iu 10 Ampoules 0 (ex stock)

100 Ampoules

94.00 18‐007‐6470(AM)

240,828 Novartis S A (Pty) Ltd VBVW2 20% R 4.3700 Syntocinon 5iu 5 42 5 77.08

143 OXYTOCIN, SYNTHETIC 10 iu injec on, 1ml ampoule

3,684,530 Specpharm (Pty) Ltd VCEH8 R 3.6252 Spec‐Oxytocin 10iu 10 Ampoules 0(ex‐stock)

100 Ampoules

94.00 18‐007‐6472(AM)

144 OXYTOCIN, SYNTHETIC 5 iuERGOMETRINE MALEATE 0,5mg injec on, 1ml ampoule

331,820 Novartis S A (Pty) Ltd VBVW2 R 8.1800 Syntometrine amp 5 42 91.00 18‐007‐6474(AM)

145 PANCURONIUM BROMIDE 2mg/ml injec on, 2ml ampoule


VAJL3 R 4.2800 Pancuronium Bromide ‐ Fresenius 4mg/2ml Amp

10 30 10 93.00 18‐007‐6476(AM)

146 PANTOPRAZOLE SODIUM 42.3mg injection equivalent to PANTOPRAZOLE 40mg, 10ml vial

284,270 Litha Pharma (Pty) Ltd VGS73 R 44.9000 Pantocid 40mg injection 1 x 5 42 2 x 5 95.00 18‐175‐3528(VI)

Add 1147 PETHIDINE HCl 25mg injection, 1ml

ampoule[S6]


VAJL3 R 1.7300 Pethidine HCI ‐ Fresenius 25mg/ml Amp

10 30 10 93.00 18‐970‐3124(AM)

148 PETHIDINE HCI 50mg/ml injection, 1ml ampoule[S6]


VAJL3 R 1.2800 Pethidine HCI ‐ Fresenius 50mg/ml Amp

10 30 10 93.00 18‐007‐6519(AM)

149 PETHIDINE HCI 50mg/ml injection, 2ml ampoule[S6]


VAJL3 R 1.1900 Pethidine HCI ‐ Fresenius 100mg/2ml Amp

10 30 10 93.00 18‐007‐6540(AM)

150 PHENYLEPHRINE HCI 10mg injection, 1ml ampoule

347,030 Abbott Laboratories SA (Pty) (Ltd)

V2150 R 30.6300 Phenylephrine 5 42 5 92.00 18‐007‐6556(AM)

151 PHENYTOIN SODIUM 50mg/ml injec on, 5ml vial

731,150 Pharmacare Limited V2205 R 28.5000 Aspen Phenytoin Sod Inj 250mg/5ml 250mg/5ml Vial

42 5 x 1 98.00 18‐970‐8084(VI)

142OXYTOCIN, SYNTHETIC 5 iu injection, 1ml ampoule



Item No.



Minimum Order

Total Points

NSN

152 PLASMINOGEN ACTIVATOR, RECOMBINANT HUMAN TISSUE‐TYPE 50mg,Pack: 1x50ml vial + 1x50ml diluent vial + diluent

1,250 Ingelheim Pharmaceuticals (Pty) Ltd

VH649 R 2,843.3700 Actilyse 50 mg Treatment Set 1 14 1 90.00 18‐976‐2991(VI)

153 POTASSIUM CHLORIDE 15% m/v injection, 10ml ampoule. Label to be printed in RED LETTERING stating 'The 10ml ampoule contains 1,5g Potassium Chloride ‐ approximately equivalent to 20 millimoles each of Potassium (K+)ions and Chloride (Cl‐)ions. The solution must be diluted before use with not less than 50(fifty) time its volume of Sodium Chloride 0,9% m/v injection or other suitable diluent. Each immediate container must also have a strip label over the neck of the ampoule printed RED ON WHITE or BLACK ON RED stating 'MUST BE DILUTED/MOET VERDUN WORD.'


V4222 R 2.0500 Sabax Potassium Chlor 15% 10 ml 10 amps 1‐6 weeks ex stock

4 Boxes 95.00 18‐971‐0612(AM)

155 PROCHLORPERAZINE MESYLATE 12,5mg injec on, 1ml ampoule


V2160 R 6.5100 Stemetil Inj 12.5mg 1 42 10 93.00 18‐007‐6576(AM)

156 PROMETHAZINE HCI 25mg injection, 1ml ampoule


VAJL3 R 2.2800 Promethazine HCI ‐ Fresenius 25mg/ml Amp

10 30 10 93.00 18‐970‐3419(AM)

157 PROMETHAZINE HCI 25mg injection, 2ml ampoule


VAJL3 R 3.0300 Promethazine HCI ‐ Fresenius 50mg/2ml Amp

10 30 10 93.00 18‐970‐3420(AM)

430,884 Litha Pharma (Pty) Ltd VGS73 60% 5,50 Provive 1% 20ml 1 x 5 42 16 x 5 95.00 18‐007‐6590(AM)

Add 1 287,256 Fresenius Kabi SA (Pty)

LtdVAJL3 40% R 6.6700 Propofol 1% Fresenius 20ml Amp 5 42 5 90.65

159 PROPOFOL 10mg/ml injection, 50 ml vialFor IV Infusion

12,080 Litha Pharma (Pty) Ltd VGS73 R 34.5000 Provive 1% 50ml 1 x 5 42 3 x 5 95.00 18‐976‐3039(VI)

Add 1 & 2

161 QUININE DIHYDROCHLORIDE 300mg injec on, 1ml ampoule


VAJL3 R 7.6600 Quinine Dihydrochloride ‐ Fresenius 300mg/ml Amp

10 30 10 93.00 18‐970‐6315(AM)

162 RANITIDINE HCI 25mg/ml, 2ml ampoule

287,040 Pharmacare Limited V2205 R 9.0721 Zantac Inj 50mg/2ml 2ml Amp 42 5 x 5 98.00 18‐007‐6594(AM)

163 REMIFENTANIL HYDROCHLORIDE equivalent to REMIFENTANIL BASE 2mg injec on, 5ml vial[S6]

35,520 Pharmacare Limited V2205 R 88.6920 Ultiva 2mg Inj 5ml Vial 5ml Vial 42 1 x 5 98.00 18‐175‐7213(VI)

158PROPOFOL 10mg/ml injection, 20ml vial



Item No.



Minimum Order

Total Points

NSN

164 RISPERIDONE 25mg powder for injec on, vialWith a 3ml prefilled syringe containing 2ml diluent, two 20G needles for reconstitution, one 20G needle for intramuscular injec on

7,750 Janssen Pharmaceutica V6205 R 451.9900 Risperdal Consta 25mg 1 inj 42 1 90.00 18‐180‐3365(VI)

165 RISPERIDONE 37,5mg powder for injec on, vialWith a 3ml prefilled syringe containing 2ml diluent, two 20G needles for reconstitution, one 20G needle for intramuscular injec on

6,220 Janssen Pharmaceutica V6205 R 670.0000 Risperdal Consta 37.5mg 1 inj 42 1 90.00 18‐180‐3368(VI)

166 ROCURONIUM BROMIDE 50mg injec on, 5ml ampoule/vial

236,260 MSD (PTY) LTD V2185 R 41.3800 Esmeron 1 X 5ml vial 28 10 x 5ml vials 90.00 18‐096‐0252(VI)

167 SALBUTAMOL 0,5mg injection, 1ml ampoule

75,850 Pharmacare Limited V2205 R 38.0760 Ventolin Inj 0,5mg 1ml 1ml Amp 42 1 x 5 98.00 18‐971‐1130(AM)

168 SALBUTAMOL 1mg/ml injection, 5ml ampouleFor IV Infusion

12,000 Pharmacare Limited V2205 R 113.4300 Ventolin Solution 5mg (1mg/ml) 5ml Amp 42 1 x 10 98.00 18‐971‐1118(AM)

169 SODIUM BICARBONATE 4% m/v injection, 50ml ampoule/plastic containerFor IV InfusionThe label must state the concentration in mmol/litre and have the name featuring prominently


VAJL3 R 29.4100 Sodium Bicarbonate 4%m/v 50ml 1 30 50 93.00 18‐035‐8064(BG)

170 SODIUM BICARBONATE 8,5% m/v injection, 50ml ampoule/plastic containerFor IV InfusionThe label must state the concentration in mmol/litre and have the name featuring prominently


VAJL3 R 25.3700 Sodium Bicarbonate 8.5%m/v 50ml 1 30 50 93.00 18‐035‐8068(BG)

171 SODIUM CHLORIDE 0,9% m/v, 5ml ampouleSuitable clear plas c container


VAJL3 R 0.8600 Euromed 0.9% Sodium Chloride 5ml 50 42 50 93.00 18‐970‐0087(AM)


V4222 60% R 0.7535 Sabax Sod Chlor 0,9% 10 ml 100 1‐6 weeks ex stock

7 boxes 95.77 18‐970‐0088(AM)


VAJL3 40% R 0.7600 Sodium Chloride 0.9% "Flexivials" 10ml

50 42 50 93.00172

SODIUM CHLORIDE 0,9% m/v injec on, 10ml ampouleSuitable clear plas c container



Item No.



Minimum Order

Total Points

NSN

173 SOMATROPIN 15iu injection, 1.5 prefilled pen and cartridge

12,680 Novo Nordisk (Pty) Ltd V2743 R 351.1200 Norditropin Nordilet 5mg 1 10 1 92.00 18‐180‐8985(EA)

174 SOMATROPIN 16iu (5,3mg) powder for injec on, unitUnit = A two‐chambered vial with LYOPHILLISED powder in one chamber + diluent in the other chamber

430 Pfizer Laboratories (Pty) Ltd

V2189 R 422.6300 Genotropin 16IU /ml PDR for INJ 5 42 5 90.00 18‐007‐5523(CA)

175 SOMATROPIN 18 iu (6mg) powder for injection, prefilled pen + cartridge

4,030 Eli Lilly SA (Pty) Ltd V2181 R 437.9700 Humatrope 6 mg 1 30 1 93.00 18‐095‐5336(VI)

176 SOMATROPIN 30iu injection, 1,5ml prefilled pen + cartridge

3,850 Novo Nordisk (Pty) Ltd V2743 R 702.2400 Norditropin Nordilet 10mg 1 10 1 92.00 18‐179‐9365(EA)

177 SOMATROPIN 36 iu (12mg) powder for injection, prefilled pen + cartridge

2,710 Eli Lilly SA (Pty) Ltd V2181 R 875.9300 Humatrope 12 mg 1 30 1 93.00 18‐095‐5337(VI)

180 SUFENTANIL CITRATE 50mcg/ml injec on, 5ml ampoule For IV use [S6]

4,070 PHARMA‐Q (PTY) LTD V1NK1 R 89.9900 Pharma‐Q Sufentanil 10 42 10 98.00 18‐007‐6782(AM)

181 SUFENTANIL CITRATE 5mcg/ml injec on, 10ml ampoule For IV use [S6]


182 SUFENTANIL CITRATE 5mcg/ml injec on, 2ml ampoule[S6]For IV use


183 SUXAMETHONIUM CHLORIDE 50mg/ml injec on, 2ml ampoule


VAJL3 R 2.4900 Suxamethonium ‐ Fresenius 50mg/ml Amp

10 30 10 93.00 18‐007‐6785(AM)

185 TESTOSTERONE CYPIONATE 100mg/ml injec on, 10 ml vial


V2189 R 144.0327 Depo‐Testosterone 1 42 1 90.00 18‐970‐5469(VI)

187 TETRACOSACTIDE 1mg injection, 1ml ampoule

300 Novartis S A (Pty) Ltd VBVW2 R 88.3400 Synacthen depot 1mg inject amp 1 42 91.00 18‐971‐2155(AM)

188 THIOPENTONE SODIUM 0,5g injecton, 20ml vial


VAJL3 R 18.6200 Thiopentone ‐ Fresenius 0.5g/20ml Amp

10 42 10 93.00 18‐971‐1002(AM)

189 TOTAL PHOSPHOLIPIDS 100mg injec on, 4ml vial For Endotracheal use


VUV35 R 1,278.6200 Survanta 4ml 4ml 21 1 90.00 18‐177‐2157(VI)

191 TOTAL PHOSPHOLIPIDS 200mg injec on, 8ml vial For Endotracheal use


VUV35 R 2,556.8600 Survanta 8ml 8ml 21 1 90.00 18‐975‐3628(VI)

193 TRAMADOL HCI 50mg per ml injec on, 2ml ampoule

429,100 Litha Pharma (Pty) Ltd VGS73 R 3.0000 Dolotram 1 x 5 42 25 x 5 95.00 18‐012‐4495(AM)

Add 1



Item No.



Minimum Order

Total Points

NSN

194 TRANEXAMIC ACID 100mg/ml injec on, 5ml ampoule


V2189 R 56.4824 Cyklokapron IV 500mg INJ 5ml 5 42 5 90.00 18‐007‐6981(AM)

195 VALPROATE SODIUM 400mg injec on, vial + Diluent For IV Infusion


V2160 R 102.5500 Epilim IV 400mg 1 42 1 93.00 18‐026‐1210(VI)

196 VECURONIUM BROMIDE 4mg powder for injec on, 2ml ampoule

211,740 Litha Pharma (Pty) Ltd VGS73 R 11.9500 Muscuron 1 x 10 42 4 x 10 95.00 18‐007‐6993(AM)

Add 1197 VECURONIUM BROMIDE 10mg

powder for injec on, 5ml vial 26,840 MSD (PTY) LTD V2185 R 56.3200 Norcuron 1 x 5ml vial 28 10 X 5ml vials 90.00 18‐185‐8389(VI)

198 VERAPAMIL HCI 2,5mg/ml injection, 2ml ampoule

21,360 PHARMA‐Q (PTY) LTD V1NK1 R 1.8800 Pharma‐Q Verapamil 10 42 530 98.00 18‐007‐6998(AM)

199 VIT. B COMPLEX injection, 10ml ampoule/vialFor IM use

287,860 Pharmacare Limited V2205 R 7.1820 A‐Lennon Vitamin B Complex Inj 10ml 10ml Vial 42 3 x 10 92.94 18‐970‐0106(VI)

200 VIT. B1 (THIAMINE HCI) 100mg/ml injec on, 10ml vial

122,130 Pharmacare Limited V2205 R 20.2920 Thiamine Hydrochloride Inj 10ml Vial 42 1 x 10 98.00 18‐970‐0006(VI)

201 VIT. B12 (CYANOCOBALAMIN) 1 000mcg injec on, 1ml ampoule

403,730 Pharmacare Limited V2205 R 4.5828 A‐Lennon Vitamin B12 1ml Inj 1ml Amp 42 5 x 10 98.00 18‐971‐5773(AM)

202 VIT. B12 (CYANOCOBALAMIN) 1 000mcg/ml injec on, 10ml vial

21,510 Pharmacare Limited V2205 R 11.3772 A‐Lennon Vitamin B12 10ml Inj 10ml Vial 42 3 x 10 98.00 18‐970‐4632(VI)

203 VIT. C (ASCORBIC ACID) 100mg/ml injec on, 5ml ampouleFor IV use


VAJL3 R 7.1400 Ascorbic Acid ‐ Fresenius 500mg/5ml Amp

10 30 10 93.00 18‐970‐0008(AM)

204 VIT. K (PHYTOMENADIONE) 2mg injec on, 0,2ml ampouleFor IV/IM use

2,256,570 ROCHE PRODUCTS (PTY) LTD

V2177 R 8.2900 Konakion MM Paediatric 5 28 5 91.00 18‐095‐3330(AM)

205 VIT. K (PHYTOMENADIONE) 10mg injec on, 1ml ampouleFor IV use

325,440 Roche Products (Pty) Ltd V2177 R 14.5100 Konakion 10 28 10 91.00 18‐014‐6851(AM)

206 WATER FOR INJECTIONS B.P., 5ml ampoulePacked in CLEAR PLASTIC container with non‐resealable closure

1,667,330 Fresenius Kabi South Africa (Pty) Ltd

VAJL3 R 0.4600 Euromed Sterile Water for Injection 5ml

50 42 50 93.00 18‐970‐0107(AM)




100 42 100 93.00 18‐971‐0871(AM)




100 42 100 93.00 18‐971‐0862(AM)

209 ZUCLOPENTHIXOL ACETATE 50mg injec on, 1ml ampouleFor IM use only

109,930 Lundbeck SA Pty Ltd VVS90 R 69.5100 Clopixol 50mg Accuphase 1 10 working days

10 90.00 18‐975‐3243(AM)



Item No.



Minimum Order

Total Points

NSN

210 ZUCLOPENTHIXOL DECANOATE 200mg injec on, 1ml ampoule For IM use only

859,890 Lundbeck SA Pty Ltd VVS90 R 36.4900 Clopixol Depot 200mg 1 x 5 10 working days

5 x 5 90.00 18‐005‐7631(AM)


Special Requirements and Conditions of Contract

HP06-2012 SVP

SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN ADMINISTRATION DEVICES TO THE

DEPARTMENT OF HEALTH

FOR THE PERIOD 1 JUNE 2012 TO 31 MAY 2014

VALIDITY PERIOD 120 DAYS

National Department of Health

Special Requirements and Conditions of Contract – HP06-2012SVP

2

CONTENTS

1. SPECIAL CONDITIONS OF CONTRACT................................................................................ 4

2. EVALUATION CRITERIA ........................................................................................................ 4

3. PRE AWARD SUPPLIER DUE DILIGENCE............................................................................ 6

4. PARTICIPATING AUTHORITIES ............................................................................................ 6

5. CONTRACT PERIOD .............................................................................................................. 6

6. RESPONSE FIELDS ............................................................................................................... 6

7. VALUE ADDED TAX ............................................................................................................... 6

8. TAX CLEARANCE CERTIFICATE .......................................................................................... 7

9. AUTHORISATION DECLARATION AND LEGISLATIVE REQUIREMENTS .......................... 7

9.1 DECLARATION OF AUTHORISATION .................................................................................. 7

9.2 LEGISLATIVE REQUIREMENTS ........................................................................................... 8

9.3 NON COMPLIANCE ............................................................................................................... 9

10. CONTRACT ADMINISTRATION ............................................................................................. 9

11. COUNTER CONDITIONS ...................................................................................................... 10

12. PROHIBITION OF RESTRICTIVE PRACTICES.................................................................... 10

13. FRONTING ............................................................................................................................ 11

14. PRODUCT COMPLIANCE .................................................................................................... 11

14.1 PRE AWARD PRODUCT COMPLIANCE PROCEDURES ................................................... 11

14.2 SAMPLES............................................................................................................................. 12

15. PRICE QUALIFICATION AND CONTRACT PRICE ADJUSTMENT PROCEDURE.............. 13

15.1 PRICING STRUCTURE........................................................................................................ 13

15.2 PRICE ADJUSTMENTS ....................................................................................................... 13

15.3 PRICE ADJUSTMENT PERIODS......................................................................................... 17

15.4 RATES OF EXCHANGE (ROE) – BASE AND AVERAGE RATES ....................................... 17

15.5 GENERAL ............................................................................................................................ 18

16. QUANTITIES, ORDERS AND DELIVERY............................................................................. 18

16.1 DELIVERY ADHERENCE..................................................................................................... 18

16.2 QUANTITIES AND ORDERS................................................................................................ 19

16.3 MANUFACTURING INFORMATION..................................................................................... 21

17. PACKAGING ......................................................................................................................... 21

18. LABELS AND PACKAGE INSERTS..................................................................................... 21


3

19. CONTAINERS ....................................................................................................................... 22

20. STERILITY............................................................................................................................. 22

21. BARCODES .......................................................................................................................... 22

22. INSPECTION AND ASSAY ................................................................................................... 23

23. QUALITY ............................................................................................................................... 23

24. SHELF-LIFE .......................................................................................................................... 23

25. POST AWARD MONITORING............................................................................................... 24

26. REPORTING AND HISTORICAL DATA................................................................................ 24

26.1 HISTORICAL DATA.............................................................................................................. 24

26.2 PERFORMANCE MEASURES ............................................................................................. 25

26.2.1 SUPPLIERS MEASURES..................................................................................................... 25

26.2.2 END USER MEASURES ...................................................................................................... 25

27. CONTACT DETAILS ............................................................................................................. 25


4

1. SPECIAL CONDITIONS OF CONTRACT

This bid and all contracts emanating there from will be subject to the General

Conditions of Contract issued in accordance with Treasury Regulation 16A

published in terms of the Public Finance Management Act, 1999 (Act 1 of

1999). The Special Conditions of Contract are supplementary to that of the

General Conditions of Contract. Where, however, the Special Conditions of

Contract are in conflict with the General Conditions of Contract, the Special

Conditions of Contract will prevail.

2. EVALUATION CRITERIA

Preference Points System

a. In terms of regulation 6 of the Preferential Procurement Regulations pertaining

to the Preferential Procurement Policy Framework Act, 2000 (Act 5 of 2000),

responsive bids will be adjudicated by the Department of Health on the 90/10-

preference point system in terms of which points are awarded to bidders on

the basis of:

- The bid price (maximum 90 points)

- B-BBEE status level of contributor (maximum 10 points)

b. The following formula will be used to calculate the points for price:

Ps = 90 min

min1

PPPt

Where

Ps = Points scored for comparative price of bid under consideration

Pt = Comparative price of bid under consideration

Pmin = Comparative price of lowest acceptable bid


5

A maximum of 10 points may be allocated to a bidder for attaining their B-BBEE status

level of contributor in accordance with the table below:

B-BBEE Status Level of Contributor Number of Points

1 10

2 9

3 8

4 5

5 4

6 3

7 2

8 1Non-compliant contributor 0

c. Bidders are required to complete the preference claim form (SBD 6.1) in order

to claim the B-BBEE status level points.

d. The points scored by a bidder in respect of the level of B-BBEE contribution

will be added to the points scored for price.

e. Only bidders who have completed and signed the declaration part of the

tender documentation may be considered.

f. The Department of Health may, before a bid is adjudicated or at any time,

require a bidder to substantiate claims it has made with regard to preference.

g. The points scored will be rounded off to the nearest 2 decimals.

h. In the event that two or more bids have scored equal total points, the contract

will be awarded to the bidder scoring the highest number of preference points

for B-BBEE.

i. A contract may, on reasonable and justifiable grounds, be awarded to a bid

that did not score the highest number of points.

j. The Department of Health reserves the right to negotiate prices

k. The Department of Health reserves the right to negotiate minimum order

quantities and not award to the highest scoring bidder if minimum order

quantities are deemed to be not reasonable.

l. The Department of Health reserves the right not to award a line item.


6

3. PRE AWARD SUPPLIER DUE DILIGENCE

The Department of Health reserves the right to conduct supplier due diligence

prior to final award. This may include site visits.

4. PARTICIPATING AUTHORITIES

The National Department of Health and the following Provincial Departments

will participate in this contract:

Provincial Departments of Health: Eastern Cape, Free State, Gauteng,

KwaZulu-Natal, Limpopo, Mpumalanga, Northern Cape, North West and

Western Cape

5. CONTRACT PERIOD

The contract period shall be for a period of 24 months commencing 1 June

2012 to 31 May 2014.

6. RESPONSE FIELDS

It is imperative that bidders submit responsive bids by completing all the

mandatory response fields for the individual items. In this regard bidders’

attention is drawn to the response field and price structure explanations and

examples supplied in the bid document.

Non-compliance with this condition may invalidate the bid for the item/s

concerned.

7. VALUE ADDED TAX

All bid prices must be inclusive of 14% Value-Added Tax.

Failure to comply with this condition may invalidate the bid


7

8. TAX CLEARANCE CERTIFICATE

An original and valid Tax Clearance Certificate issued by the South African

Revenue Services certifying that the tax affairs of the bidder are in order must

be submitted at the closing date and time of bid. Copies or certified copies of

the Tax Clearance Certificate will not be acceptable. Failure to comply with this

condition will invalidate the bid.

9. AUTHORISATION DECLARATION AND LEGISLATIVE

REQUIREMENTS

9.1 DECLARATION OF AUTHORISATION

a. In the event of the bidder not being the actual manufacturer and will be

sourcing the product(s) from another company (third party), a signed letter from

the source company to the bidder committing to firm supply arrangement(s) for

each item, including lead times in this regard, must accompany your bid at

closing date and time. The Bid Authorization Form (Form AD1) must be

completed and signed giving full details of the declaration of authorisation and

be submitted with bid documents at the closing date and time of the bid.

b. The said company/manufacturer/supplier issuing such a letter must confirm

that it has familiarised itself with the item description/specification, lead times

and bid conditions and if the bid consists of more than one item, it should be

clearly indicated in respect of which item(s) the supportive letter has been

issued.

c. The Department reserves the right to verify any information supplied by the

bidder in the Authorisation Declaration and should the information be found to

be false or incorrect, the Department of Health will exercise any of the

remedies available to it in the bid documents.

d. The bidder must ensure that all financial and supply arrangements for goods,

including lead times, have been mutually agreed upon between the bidder and

the third party. No agreement between the bidder and the third party will be

binding on the Department of Health.


8

e. It must be indicated in the letter that all the terms and conditions are mutually

agreed upon.

f. Failure to submit a duly completed and signed Authorisation Declaration, with

the required annexure(s), in accordance with the above provisions may

invalidate the bid for such goods offered.

9.2 LEGISLATIVE REQUIREMENTS

a. Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of

1978) and the Trade Marks Act, 1993 (Act 194 of 1993) as amended.

Bidders must submit a copy of the actual patent or an agreement with the

patent holder with the bid document at the closing date and time of the bid.

b. Bidders must comply with any legal requirements with regard to voluntary

licenses obtained, and proof of agreements in this regard must be supplied

with the bid document at the closing date and time of the bid.

c. The bidder offering medicines in terms of this bid must be licensed with the

Medicines Control Council (MCC) in terms of section 22C (1) (b) of the

Medicines and Related Substances Act, Act 101 of 1965, as amended, and

must be the holder of the license according to section 22C (6) of the said Act. A

certified copy of the licence including all annexures thereto must be submitted

with the bid document, at the closing date and time of bid.

d. Medicines offered by bidders must be registered in terms of section 15 of the

Medicines and Related Substances Act, Act 101 of 1965 as amended, and

bidders must indicate on the item response field the registration number of

such an item in terms of the said Act. The medicines must comply with the

conditions under which the medicine is registered at the closing date and time

of bid. Certified copies of product registration certificates with the MCC should

accompany the bid at closing date and time.

e. The bidder must submit proof of current GMP compliance of all manufacturing,

packing and laboratory sites used for each product and disclose any notice of

deviation from GMP received from the MCC.

f. The bidder must submit a certified copy of a valid certificate of Registration as a

Responsible Pharmacist with the South African Pharmacy Council.


9

9.3 NON COMPLIANCE

Non compliance with the above mentioned (Paragraphs 9.1 and 9.2) special

conditions may invalidate the bid for such products offered.

10. CONTRACT ADMINISTRATION

a. Successful bidders must advise the Cluster Manager: Pharmaceutical Policy

and Planning immediately when unforeseeable circumstances will adversely

affect the execution of the contract. Full particulars of such circumstances as

well as the period of delay must be furnished within a week of identifying such

a problem.

b. The administration and facilitation of the contract will be the responsibility of

National Department of Health and all correspondence in this regard must be

directed to one of the following addresses:

Director: Affordable Medicines

Department of Health

Private Bag X828

PRETORIA 0001

Civitas Building

Room 501 South Tower

242 Struben Street

PRETORIA 0002

c. The Department of Health may communicate with bidders where clarity is

sought after the closing date of the bid and prior to the award of the contract, or

to extend the validity period of the bid, if necessary.

d. All communication between the bidder and the Department of Health must be

done in writing.

e. Any communication to any government official or a person acting in an advisory

capacity for the Department in respect of this bid between the closing date and

the award of the bid by the bidder is discouraged.


10

11. COUNTER CONDITIONS

Bidders’ attention is drawn to the fact that amendments to any of the Bid Conditions or

setting of counter conditions by the bidders may result in the invalidation of such bids.

12. PROHIBITION OF RESTRICTIVE PRACTICES

a. In terms of section 4 (1) of the Competition Act No. 89 of 1998, as amended,

an agreement between, or concerted practice by, firms, or a decision by an

association of firms, is prohibited if it is between parties in a horizontal

relationship and if a bidder(s) is / are or a contractor(s) was / were involved in:

directly or indirectly fixing a purchase or selling price or any other trading

condition;

dividing markets by allocating customers, suppliers, territories or specific

types of goods or services; or

collusive bidding.

b. If a bidder(s) or contractor(s), in the judgment of the purchaser, has / have

engaged in any of the restrictive practices referred to above, the purchaser

may refer the matter to the Competition Commission for investigation and

possible imposition of administrative penalties as contemplated in the

Competition Act No. 89 of 1998.

c. If a bidder(s) or contractor(s) has / have been found guilty by the Competition

Commission of any of the restrictive practices referred to above, the purchaser

may, in addition and without prejudice to any other remedy provided for,

invalidate the bid(s) for such item(s) offered, and / or terminate the contract in

whole or part, and / or restrict the bidder(s) or contractor(s) from conducting

business with the public sector for a period not exceeding ten (10) years and /

or claim damages from the bidder(s) or contractor(s) concerned.


11

13. FRONTING

a. The National Department of Health supports the spirit of broad based black

economic empowerment and recognizes that real empowerment can only be

achieved through individuals and businesses conducting themselves in

accordance with the Constitution and in an honest, fair, equitable, transparent

and legally compliant manner. Against this background the National Department

of Health condemns any form of fronting.

b. The National Department of Health, in ensuring that bidders conduct

themselves in an honest manner will, as part of the bid evaluation processes,

conduct or initiate the necessary enquiries/investigations to determine the

accuracy of the representation made in bid documents. Should any of the

fronting indicators as contained in the Guidelines on Complex Structures and

Transactions and Fronting, issued by the Department of Trade and Industry, be

established during such enquiry / investigation, the onus will be on the bidder /

contractor to prove that fronting does not exist. Failure to do so within a period

of 14 days from date of notification may invalidate the bid / contract and may

also result in the restriction of the bidder / contractor to conduct business with

the public sector for a period not exceeding ten (10) years, in addition to any

other remedies the National Department of Health may have against the bidder /

contractor concerned.

14. PRODUCT COMPLIANCE

14.1 PRE AWARD PRODUCT COMPLIANCE PROCEDURES

The following pre-award product compliance procedures will apply:

a. Compliance to specifications as stated in the bid document.

b. Certified copy of product registration with Medicines Control Council (MCC)

where applicable

c. Compliance to Good Manufacturing Practice where applicable


12

d. Valid relevant licence from Medicines Control Council where applicable

e. Submission of samples of the relevant products on or before the closing date

and time of the bid at the addresses indicated in paragraph 14.2

14.2 SAMPLES

a. No samples must be sent to the Pharmaceutical Policy and Planning unit of

the National Department of Health.

b. Samples must be submitted to each of the addresses indicated below, to be

received before or at closing date and time of bid:

Ms Santie Van Dyk

Tel: 011 628 9003

Gauteng: Medical Supplies Depot

Store 3

35 Plunkett Avenue

Hurst Hill 2092

Ms Helen Hayes

Tel: 021 483 4567

Western Cape: Department of Health

Pharmaceutical Services

4 Dorp Street Room T14-02

Cape Town 8001

c. For accurate evaluation of samples, bidders must submit in original packaging at

least the following minimum quantities:

Injectables – three ampoules or three vials

All other dosage forms – at least one original pack

Devices – One original pack / box

d. Bids not supported by samples will be disregarded in respect of the items for

which samples are not submitted.

e. Samples of items offered must be marked with the bid number, the item number

as well as the bidder’s name and address.

f. It is the responsibility of the bidders to ensure receipt of the samples at the testing

authorities described in section 14.2 (b).

g. Samples submitted by unsuccessful bidders must be collected by them within 3

months of the commencement of the contract. Samples not collected within this 3


13

month period will be destroyed.

h. Samples of all products accepted against this bid will be retained for the duration

of the contract period.

i. All samples must be a true representation of the product which will be supplied.

j. All samples of registered medicines must be submitted with the MCC

approved/registered package insert.

15. PRICE QUALIFICATION AND CONTRACT PRICE ADJUSTMENT PROCEDURE

15.1 PRICING STRUCTURE

a. Prices submitted for this bid will be regarded as non-firm and subject only to

adjustment(s) in terms of the formula under paragraph 15.2, defined areas of cost

and defined periods of time.

b. Bidders are advised to refer to the Reference Price List for specific small volume

parenterals published on the Department of Health website (www.doh.gov.za)

before preparing the bid submission

c. Bidders should quote a final delivered price.

d. Final price must include Active Pharmaceutical Ingredient (API) price, formulation

cost, transport cost, Value Add Tax, etc. Bidders are referred to the pricing

schedule in this regard.

e. Bidders should note that margins above cost cannot be adjusted.

15.2 PRICE ADJUSTMENTS

a. The Department of Health reserves the right to accept or reject any application for

price adjustment.

b. Bidders are required to complete the price breakdown in the relevant response

fields as per diagram below. Failure to provide such breakdown may exclude the

bidder from any price adjustments during the contract period.


14

Cost component

(For fully imported or finished products offered

from another manufacturer, API and formulation components may be

combined)

% of total product value

(values in this column must add up to 100%)

Value

(Value for “% imported” and “% local” must add up to 100% for

each cost component)

% imported % local

API

Formulation cost

Transportation cost N/a

Margin N/a N/a

c. An electronic price adjustment calculator will be available on the Department of

Health’s website. Applications for price adjustments must be submitted

electronically using the electronic price adjustment calculator. Signed printed

copies of the calculations must also be submitted along with documentary

evidence in support of any adjustment.

d. The process for price adjustment will be as follows:

Identify the cost component(s) to be adjusted. Margins above cost

cannot be adjusted, thus eligible cost components include:

o Cost of the API

o Costs related to formulation

o Costs related to transport

Calculate price adjustment using the following formula:

RA1 RF1 RT1

Pa = Pt DA RA0 + DF RF0 + DT RT0 + PM

RA1 RF1 RT1

Pa = Pt DA RA0 + DF RF0 + DT RT0 + PM

Pa = The new price to be calculated


15

Pt = Original award price. Note that Pt must always be the original award price

DA = The proportion of the award price attributable to API cost

RA1 = New cost of the API

RA0 = Base cost of the API

DF = The proportion of the award price attributable to formulation cost

RF1 = The new cost of formulation

RF0 The base cost of formulation

DT The proportion of the award price attributable to transport cost

RT1 The new cost of transport

RT0 The base cost of transport

PM The proportion of the award price that is attributable to margin above cost; this variable is not adjustable

e. Costs associated with normal business risk are not eligible for adjustment, but

unforeseen costs that may impact continuous supply will be considered.

f. Applications for price adjustments may be submitted by the half-yearly review dates

stipulated in section 14.3 and must be accompanied by documentary evidence of the

circumstances that are claimed to warrant a price adjustment. The Department of

Health reserves the right to make further requests for additional documentation to

support a price change in addition to the documentation that may have already been

submitted by the supplier.

g. Information required to assess price adjustment requests is as follows:

For adjustments related to API price changes, suppliers must submit the

following:

o Documentation of the current cost of the API

o Documentation of the new cost of the API


16

For adjustments related to formulation or transport price changes, suppliers

must submit the following:

o A description of why the adjustment is necessary

o Documentation of the current cost of the cost component

o Documentation of the new cost of the cost component

h. Successful bidders can apply for adjustments relating to one or more than one

combination of the above factors.

i. All documentation supplied in support of a bid must be directly linked to the specific

product and the specific supplier

j. Contracted suppliers are expected to continue to supply the product without

interruption at the contracted price until advised of the outcome of a price

adjustment application.

k. No retroactive price increases will be permitted for purchase orders already issued

to and accepted by the manufacturer.

l. Where the Department of Health is not satisfied with the documentation submitted,

it could grant a lower adjustment or deny the request altogether.

m. All requests for price adjustments will be based on the original award price – and

not on any previously adjusted price.

n. Should the Department of Health choose to initiate a price adjustment (decrease)

for a particular product, the following factors will be taken into account to determine

the revised prices:

Material reductions in the cost of the API, as determined by a composite

index of API costs linked to international prices for products in question;

Feasibility of using an alternate source if a cheaper source of APIs is

available at the requisite quality level;

Time needed to implement necessary changes in raw material or API sources

as determined by regulatory processes mandated by the MCC and other

regulatory bodies in question;

Other material reductions in the cost of Production based on changes in

technology or alternate routes of production becoming available or

substantially higher volumes than anticipated resulting in a drop in fixed

manufacturing costs.


17

15.3 PRICE ADJUSTMENT PERIODS

Adjustment to contract prices may be applied for at the following dates:

Adjustment

Application for price adjustment to reach the office by the following dates

Dates from which adjusted prices will become effective

1st Adjustment 5 November 2012 1 December 2012

2nd Adjustment 5 May 2013 1 June 2013

3rd Adjustment 5 November 2013 1 December 2013

15.4 RATES OF EXCHANGE (RoE) – BASE AND AVERAGE RATES

In the event where material and/or finished products are imported the following will

apply:

a. The formula described in par. 15.2 will be used and ONLY the imported cost

component of the bid price will be adjusted taking into account the base RoE and

the average RoE rate over the period under review indicated in paragraph (d)

below.

b. Rate(s) of exchange to be used in this bid in the conversion of the price of the

item(s) to South African currency.

Currency Rates of exchangeAverage for the period 1 November 2011 to 31 January 2012

US Dollar R 8.1151

Pound Sterling R 12.6947

Euro R 10.7342

Yen R 0.1049

c. Should the bidder make use of any other currency not mentioned above, the bidder

is requested to calculate the average for the period 1 November 2011 to 31

January 2012 using the South African Reserve Bank published rates for the specific

currency. Visit www.reservebank.co.za to obtain the relevant rates.

d. Contract price adjustments due to rate of exchange variations are based on

average exchange rates as published by the Reserve Bank for the periods indicated

hereunder:

http://www.reservebank.co.za/


18

Adjustment Average exchange rates for the period:

1st Adjustment 1 February 2012 – 31 October 2012

2nd Adjustment 1 November 2012 – 30 April 2013

3rd Adjustment 1 May 2013 – 31 October 2013

15.5 GENERAL

a. Unless prior approval has been obtained from National Department of Health, no

adjustment in contract prices will be made.

b. Contract Price Adjustment (CPA) applications will be applied strictly according to

the specified formula and variables above as well as the cost breakdown supplied

by successful bidders in their bid documents.

c. In the event where the supplier’s CPA application, based on the above formula and

parameters, differs from National Department of Health’s verification, National

Department of Health will consult with the supplier to resolve the differences.

d. Bidders are referred to paragraph 11 of the Special Conditions regarding counter

conditions.

16. QUANTITIES, ORDERS AND DELIVERY

16.1 DELIVERY ADHERENCE

a. For each product, bidders must explicitly indicate the minimum and maximum

volumes that they can supply on a monthly, quarterly (3-monthly) and annual basis

on the response fields.

b. Ability to supply must be maintained throughout the duration of the contract.

c. Bidders must indicate and provide assurance of ability to maintain delivery lead time

(time from placement of the order to delivery at the provincial medical store or

delivery point) of not more than 6 weeks for the duration of the contract.

d. Delivery of products must be made in accordance with the instructions appearing on

the official order forms emanating from the above mentioned Participating

Authorities and institutions placing the orders.

e. All deliveries or dispatches must be accompanied by a delivery note stating the


19

official order number against which the delivery has been effected.

f. In respect of items awarded to them, contractors must adhere strictly to the delivery

periods quoted by them in their bids.

g. The instructions appearing on the official order form regarding the supply, dispatch

and submission of invoices must be strictly adhered to.

h. All invoices should be delivered / posted to reach the institution that placed the

order timeously. The invoices should be original and accompanied by proof of

delivery.

i. Deliveries must be in accordance with official orders and any deviation will be

returned to the contractor at the contractor’s expense.

j. Deliveries must conform to cold chain distribution requirements, if applicable.

Normal storage conditions (25 degrees Celsius) must not be exceeded.

16.2 QUANTITIES AND ORDERS

a. The ordered quantities are required for delivery as indicated by the particular

participating departments.

b. Suppliers should under no circumstances deviate from the orders issued by the

departments.

c. The Department of Health is under no obligation to purchase any stock, which is in

excess of the indicated quantities for any item.

d. The quantity indicated against each item represents the total estimated off-take of

all participating departments as per paragraph 4.

e. Bidders should note that the order/s will be spread out throughout the contract

period and that delivery points will be to the individual Provincial Depots or

institutions.

f. Bids must be for supply ex duty paid stocks held in the Republic of South Africa

during the contract period.

g. The quantities reflected in the bid documents are estimated quantities and no

guarantee is given or implied as to the actual quantity which will be ordered.

h. The Department of Health also reserves the right to purchase its requirements

elsewhere outside the contract in terms of clause 21 of the General Conditions of

Contract if:

Minimum order quantity specified by the contractor be more than that


20

of an institution’s requirementsThe item(s) are urgently required and not immediately availableAn emergency arisesIf the contractor fails to perform in terms of this contract

i. The Department of Health reserves the right to arrange contracts with more than

one contractor for the same item but not exceeding three contractors subject to the

following condition:

In a split or multiple award a single bidder will not be awarded more than one portion for the same line item. The Department of Health reserves the right not to split award amongst bidders using the same API source and / or manufacturer.

j. The allocation of volumes between two suppliers will be determined based on the

difference in points, as follows:

Category Difference between points Recommended percentage split

A Equal points 50/50

B 0,1% – 5 % 60/40

C 5,1% - 10% 70/30

D 10,1% – 20 % 80/20

k. The Department of Health reserves the right to determine the number of awards per

line item in cases where there are several bids with point totals that are within 20%

of the bid with the highest number of points. Only bids that are within 20% of the

highest bid score will be considered for splits.

l. For multiple awards of the same item to three bidders the volume will be allocated

according to the following formula in line with paragraph 15.2 k:

Supplier portion = 33.3% + [Supplier score – Mean score] * 2.3 percentage points

m. The Department of Health reserves the right to change drug regimens and/or

product formulations if necessary due to emerging clinical evidence, disease

profiles, reported adverse drug reactions or resistance patterns.


21

16.3 MANUFACTURING INFORMATION

a. Bidders must disclose the manufacturing site(s) as well as the API supplier(s), as

approved by or submitted to the MCC.

b. Bidders must be able to substantiate the API price provided.

17. PACKAGING

a. All deliveries made against this contract whether by road or rail are to be packed in

containers, which will be acceptable for further dispatch by rail. Attention is drawn

to the requirements of the Transnet Freight Rail Standard Conditions of Carriage

Policy.

b. The number of “PACK” items in the commercial packing must appear on the bid

documents. The packing must be uniform for the duration of the contract period,

i.e.:

The number of “PACK” items per commercial packing.

The number of commercial packing per carton.

The number of cartons per bulk packing.

The conditions under which the product must be stored.

c. The following information must be clearly and indelibly printed on all inner and outer

bulk packing in letters not less than 10mm in height:

Name and strength of item and quantity

Date of manufacture.

Expiry date.

Batch number.

18. LABELS AND PACKAGE INSERTS

Labels and package inserts for medicines intended for administration to humans,

must comply with the Medicines and Related Substances Act, 1965 (Act 101 of

1965) as amended.


22

19. CONTAINERS

The function of a container for a medicinal preparation is to maintain the quality,

safety and stability of its contents. Containers should withstand the mechanical

hazards of handling and transport, prevent leakage, breakage and provide an

appropriate level of protection from environmental conditions. Conditions of

container must be acceptable to purchaser at the point of delivery. Ideally, the

materials of construction should have no chemical or physical effect on the

preparation, and, for liquid preparations, should be sufficiently transparent to permit

inspection of the contents whilst providing protection from incident radiation when

necessary. B.P.C.11th edition p. 630.

20. STERILITYa. All injectable preparations are to be supplied sterile and apyrogenic.

b. The conditions under which medical devices offered on this bid should be sterilised,

shall comply with the relevant following South African Bureau of Standards Codes of

Practices:

The Industrial Sterilisation of Medical Products. Part I: Gamma Radiation facilities SABS 0185: Part I: - 1982

The Installation and Safe Use of Ethylene Oxide (EO) Sterilisers in Hospitals and Industry. SABS 0213 - 1987

ISO 7439:2002/FDAM 1

21. BARCODES

a. It is a specific condition of all pharmaceutical bids that the packaging of all products

supplied to the Department of Health must include a barcode (number plus

symbology). Both the outer case and the specification pack must be marked with

the appropriate number and symbology. The European Article Numbering Code 13

(EAN 13) has been accepted as standard. The batch number and the expiry date

should be included in the barcode, if possible.

b. Bidders who are already in possession of the necessary block of numbers are

requested to submit the EAN 13 numeric code(s) for each of the products offered as

well as the outer case coding applicable to the distribution pack(s) (ITF 14) together

with the quantity of items contained in such packs.


23

22. INSPECTION AND ASSAY

a. A valid certificate, not older than 2 years for raw materials used in the

manufacturing process must be provided when requested.

b. All deliveries to authorised participants will be subject to a visual examination and

scrutiny by the relevant participant and/or assay by the Laboratories as indicated in

paragraph 14.2

23. QUALITY

a. Products supplied in consequence of this bid must conform in every respect with the

conditions of registration lodged with Medicines Control Council throughout the

period of the contract.

b. A certified copy of a valid certificate of analysis for each batch of finished product

delivered in terms of the contract must be submitted electronically to the National

Department of Health within one (1) week after delivery.

24. SHELF-LIFE

a. Products, upon delivery, must have at least 18 months of shelf-life before date of

expiry.

b. Any delivery of short dated supplies without prior written approval must be collected

by the respective suppliers at their own cost.

c. Contractors may make written applications to deliver material with a shorter shelf-

life, provided such applications are accompanied by an undertaking that such short-

dated stock will be unconditionally replaced before or after expiry and that such

applications are approved before execution of the orders.

d. Provided also that any such written application must include an undertaking by the

contractor to apply the following discount formula when supplying short dated stock:

A = 2 (18 – months to date of expiry) % X consignment value short dated stock.

Therefore, amount to be invoiced is: Consignment value – A, where A is the


24

discount formula.

e. Any participating authority may, without prejudice, decline written applications to

deliver stock with a shelf -life of less than 15 months.

25. POST AWARD MONITORING

The contractors must confirm compliance with the Good Manufacturing Practice.

Any change in the said status during the contract period must be reported within

seven (7) days of receipt of such notice from the Medicines Control Council to:

Pharmaceutical Policy and Planning, Affordable Medicines, Department of Health,

for attention:

Ms. Helecine Zeeman

([email protected])

Director: Affordable

Medicines

Tel. No: 012 395 8530

Ms Phuti Moloko

([email protected])

Deputy Director: Procurement &

Distribution

Tel. No: 012 395 8439

26. REPORTING AND HISTORICAL DATA

26.1 HISTORICAL DATA

Historical value and volume reports are required to be submitted monthly

preferably via e-mail to the Department of Health for attention of Ms P Moloko

([email protected]), Ms M Rasengane ([email protected]) and Ms N

Scheurkogel ([email protected]) by all successful bidders. For this purpose

electronic templates which will include orders received and deliveries made will be

supplied to successful bidders. The reports must be submitted on or before the

10th of each month.

mailto:[email protected]






25

26.2 PERFORMANCE MEASURES

26.2.1 SUPPLIERS MEASURES

a. Delivery period adherence

b. Product quality adherence

26.2.2 END USER MEASURES

a. On time payment

27. CONTACT DETAILSChief Directorate: Pharmaceutical Policy and Planning, Private Bag X828,

Pretoria, 0001 or Physical address: 242 Struben Street, Civitas Building,

Pretoria, 0001.

Bid Enquiries:

Phuti Moloko:

Tel: (012) 395 8439

Fax: (012) 395 8823

[email protected]

Specification / Technical Enquiries

Mamma Rasengane

Tel: (012) 395 9452

Fax: (012) 395 8823

[email protected]



CONTRACT NUMBER HP06-2012SVP THE DEPARTMENT OF … · Novartis South Africa (Pty) Ltd P O Box 92...

Documents

Transcript of CONTRACT NUMBER HP06-2012SVP THE DEPARTMENT OF … · Novartis South Africa (Pty) Ltd P O Box 92...